About Us

Reneo is a clinical stage pharmaceutical company focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP).

Our Work

We are developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. We are initially developing REN001 in three rare genetic diseases that typically present with myopathy and have high unmet medical need: primary mitochondrial myopathies (PMM), long-chain fatty acid oxidation disorders (LC-FAOD), and glycogen storage disease type V (McArdle disease). Our experienced team of drug development experts, are dedicated and passionate about finding effective therapies for these complex rare genetic mitochondrial diseases.

Executive Leadership

Meet the Reneo Executive Team!

Gregory J. Flesher

President & Chief Executive Officer

Wendy Johnson

Chief Operating Officer

Alejandro Dorenbaum, M.D.

Chief Medical Officer

Board of Directors

About Reneo?

If you have questions about Reneo's investors or would like to learn more about our programs, please visit our Investor page.